Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Xilio Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 41 | 1 | 33 | −7 |
| Shares | 18.8M | 1.08K | 17.9M | −893.2K (−4.8%) |
| Value | $132.7M | $8.00K | $52.2M | −$80.5M (−60.7%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Xilio Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Laurion Capital Management LP | 142,900 | $417.0K | 0.02% |
| Renaissance Technologies LLC | 75,300 | $220.0K | 0.00% |
| Millennium Management LLC | 49,956 | $146.0K | 0.00% |
| Bailard, Inc. | 36,632 | $107.0K | 0.00% |
| Ergoteles LLC | 17,548 | $51.0K | 0.00% |
| RBF Capital, LLC | 10,072 | $29.0K | 0.00% |
| Cannell Capital LLC | 4,545 | $13.0K | 0.00% |
| Credit Suisse AG | 4 | $0 | 0.00% |
Sold out (15)
Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Monashee Investment Management LLC | 163,066 | $1.15M |
| Bank of New York Mellon Corp | 21,029 | $149.0K |
| Charles Schwab Investment Management Inc | 16,100 | $114.0K |
| Nuveen Asset Management, LLC | 11,284 | $80.0K |
| Granite Point Capital Management, L.P. | 10,000 | $71.0K |
| Deutsche Bank AG | 4,026 | $28.0K |
| American International Group, Inc. | 3,795 | $27.0K |
| California State Teachers Retirement System | 3,208 | $23.0K |
| Bank of America Corp | 2,611 | $19.0K |
| STRS Ohio | 1,700 | $12.0K |
| Barclays PLC | 1,243 | $8.00K |
| Amalgamated Bank | 1,078 | $8.00K |
| Legal & General Group Plc | 698 | $5.00K |
| Ameritas Investment Partners, Inc. | 573 | $4.00K |
| Royal Bank of Canada | 470 | $3.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 1,078 | $8.00K |